ArticleEuropean journal of medical research2025
CILP attenuates pulmonary fibrosis through the TGF-β1/SMAD3 pathway.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Evaluation of a Novel Inhalable Liposomal Powder Co-Encapsulating ASSNAC and Pirfenidone via Spray Freeze-Drying for Targeted Pulmonary Fibrosis Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease with poor survival, which is characterized by abnormal accumulation of fibrotic tissue in the lung parenchyma. Transforming growth factor-β1 (TGF-β) is a central profibrotic mediator, but the related mechanism of the activation of latent TGF-β has not been conclusively elucidated. A comprehensive study of mRNAs in human IPF was conducted using GSE10667 microarray data from GEO database, and the expression of cartilage intermediate layer protein (CILP) was upregulated among end-stage pulmonary fibrosis (EPF) and acute pulmonary fibrosis (APF) as compared to non-fibrosis tissues. Furthermore, CILP has protein-protein interactions with TGF-β1 through PPI analysis. Therefore, we investigated the potential effects and mechanisms of CILP in pulmonary fibrosis in pulmonary fibroblasts and BLM-induced mouse model (Eight-week-old male C57BL/6 mice, 20-22 g, purchased from the Experimental Animal Center of Guangzhou Medical University). In vitro, treatment with recombinant CILP (100 ng/mL) significantly attenuated TGF-β1-induced upregulation of collagen type I (Col1a1, p < 0.01) and α-smooth muscle actin (α-SMA, p < 0.01) in primary mouse pulmonary fibroblasts. Mechanistically, CILP suppressed TGF-β1-mediated SMAD3 phosphorylation (p-SMAD3, p < 0.001) and nuclear translocation, as confirmed by Western blotting and immunofluorescence. In the bleomycin (BLM)-induced mouse model of pulmonary fibrosis, intravenous administration of CILP (1 μg/g body weight, administered every 2 days for 4 weeks) reduced lung collagen deposition (Masson staining) by 38% (p < 0.01), lowered Ashcroft scores (from 5.8 ± 0.7 to 2.3 ± 0.4, p < 0.001), and decreased lung hydroxyproline content (a marker of collagen accumulation) by 42% (p < 0.01) compared to BLM-only controls. Clinically, serum CILP levels showed no significant difference between 17 idiopathic pulmonary fibrosis (IPF) patients and 17 non-fibrotic controls (3.2 ± 0.8 ng/mL vs. 3.5 ± 0.9 ng/mL, p > 0.05), suggesting potential lung tissue-specific action of CILP with minimal systemic off-target risk. In conclusion, CILP inhibited TGF-β1-induced fibrosis via its negative feedback loop, and may act as a promising candidate for the precaution and treatment of IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.